STAT5d
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
FierceBiotech5d
Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AZ showdown
A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...
AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein(a)
"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...
STAT4d
A win for Apellis, a setback for Astellas
The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...
Zacks.com on MSN3d
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage ...
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...
The American Journal of Managed Care5d
KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial
Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...
La Crosse Tribune1d
Do I need medicine to control cholestral problem? -- Mayo
Low-density lipoprotein (LDL) cholesterol: We call LDL "bad" cholesterol. Below 100 milligrams per deciliter (mg/dl) is ...
Too Old to Operate3d
Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults
The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a ...
Data brief: Prevalence of high total cholesterol 11.3% in US adults from Aug. 2021–Aug. 2023
The prevalence of high total cholesterol was 11.3% among U.S. adults from August 2021 to August 2023, according to a November ...
AHA 2024: Zerlasiran shows promising Phase II results for elevated lipoprotein(a)
Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...